Status:
UNKNOWN
Safety and Efficacy Investigation on the Effects of ClearSkin Non-ablative ER:Glass 1540nm Laser Module in the Treatment of Acne Scars.
Lead Sponsor:
Alma Lasers
Conditions:
Acne Scars - Mixed Atrophic and Hypertrophic
Eligibility:
All Genders
18-50 years
Phase:
NA
Brief Summary
The ClearSkin module, Er: Glass 1540nm, is largely used in the treatment of acne vulgaris and acne scars. The non-ablative ER:Glass 1540 nm laser deeply penetrates the skin, causing thermal damage to ...
Eligibility Criteria
Inclusion
- Men or women aged 18 to 50 years
- Presence of mild to moderate facial acne scars (according to Goodman \& Baron's scale)
- Subjects in reasonably good general health, according to the Investigator's judgment;
- Subjects who agree to avoid tanning during the entire investigational period;
- Subjects who agree to avoid any other facial procedure during the entire investigational period; including but not limited to: injectables or threads, peeling of any kind, dermabrasion, facial hair removal, or application of any cosmeceutical/pharmaceutical without the consent from the PI only.
- Subjects able to understand the full nature and the purpose of the investigation, including possible risks and side effects, able to cooperate with the Investigator and comply with the requirements of the entire investigation (ability to attend all the planned investigation visits according to the time limits included) based on Investigator's judgment.
- Subjects willing to sign an informed consent, consent to use their photos for future scientific or marketing purposes, according to the sponsor's needs.
Exclusion
- Subjects with active infections
- Subjects with a history of keloid scarring or hypertrophic scar formation
- Subjects with previous medical treatment of the area, or oral retinoid drug prescribed within the past six months
- Subjects who have been tanning within the past 30 days;
- Previous surgical treatment of the area selected for the treatment with the investigational device;
- Subjects with any inflammatory skin condition e.g., eczema, active herpes simplex, etc. at the treatment site;
- Subjects with the presence of tattoos at the treatment site
- Subjects with skin cancer or any other cancer and/or any cancer drug therapy (such as ducabaxine, fluorouracil, methotrexate, etc.)
- Subjects with history of autoimmune disorder or evidence of immunosuppression;
- Subjects with collagen vascular diseases
- Subjects with thrombocytopenia
- Subjects with peripheral vascular disease
- Subjects with Melasma
- Pregnant or lactating subjects
Key Trial Info
Start Date :
January 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2025
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT06102343
Start Date
January 1 2024
End Date
January 1 2025
Last Update
October 26 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Up Clinic
Lisbon, Portugal, 1400-020